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Human tgG anti-DNA antibodies deposit in kidneys and induce
proteinuria in SCID mice. We investigated the capacity of five human
monoclonal IgG anti-DNA antibodies derived from lupus patients to
produce glomerular immune deposits. The hybridomas secreting these
antibodies were administered intraperitoneally to severe combined immu-
nodeficiency (SCID) mice. Three of the five antibodies (B3, 35.21, 33.C9)
were detected in the kidneys, but only one (33.C9) deposited exclusively in
the glomeruli in the mesangium and capillary wall, whereas the other two
antibodies bound to nuclei both in the kidney and in other organs. The
antibodies were tested against a variety of autoantigens by ELISA, the
only unique feature of 33.C9 was that it also bound strongly to histones.
There were no particular amino acid motif that was related to immuno-
globulin deposition in the kidney. All the mice that had immunoglobulin
deposited in the kidney, either extracellularly or intranuclearly developed
2 to 3+ proteinuria, whereas the other mice had only trace amounts of
proteinuria. This study demonstrates that some human monoclonal IgG
anti-dsDNA antibodies are capable of binding to the glomerulus while
others can penetrate cells and bind to nuclei in vivo. Although no
abnormal pathology was observed, proteinuria was detected, perhaps
representing an early phase of disease. These results indicate that the
affinity for dsDNA is not the sole determining factor governing the
biological properties of human anti-DNA antibodies in vivo.
Anti-DNA antibodies are found in the sera of 50 to 75% of
most published series of patients with SLE, but only about 30 to
50% of patients develop renal disease. One report which corre-
lated serum anti-DNA antibodies with disease exacerbations
concluded that there was no qualitative change in these antibodies
during flares using three different assays, and that anti-DNA
antibodies were an epiphenomenon not directly linked to patho-
genesis [11. In contrast, the association between anti-DNA anti-
bodies and renal disease appears much stronger in those murine
models of SLE where the relationship between anti-DNA anti-
bodies and nephritis has been studied most extensively. In one
study almost 100% of the lupus prone mice developed nephritis
and had anti-DNA antibodies [2]. Similarly, whereas there is little
direct evidence that anti-DNA antibodies play a role in human
lupus nephritis, in elegant experiments using mouse monoclonal
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anti-DNA antibodies, Vlahakos et a! demonstrated that only a
proportion of exogenously administered murine monoclonal anti-
DNA antibodies deposited in the glomeruli and induced nephritis
in non-autoimmune mice [3]. Studies using human polyclonal
affinity-purified anti-DNA antibodies suggest that this specificity is
related to the pathogenesis of nephritis [4], but also illustrate the
weakness of drawing conclusions from serological studies or using
polyclonal preparations in which precise correlations between
specificity and function cannot be made. In the case of the human
disease where the serological association between the presence of
anti-DNA antibodies and nephritis is weaker, there are no data to
indicate which, if any, of the anti-DNA antibody population is
pathogenic. This study attempts to provide direct evidence for the
pathogenic role of human anti-DNA antibodies.
Murine monoclonal IgG anti-DNA antibodies are generated
consistently and easily from lupus mice with nephritis. We have
previously shown that the equivalent human antibodies have been
produced from only a minority of patients with active renal
disease [5, 6]. This may be due to the technical difficulties with
human hybridoma technology but, alternatively, may be a reflec-
tion of the different role anti-DNA antibodies play in the human
disease and in the animal model.
It is not possible to analyze the effects of these monoclonal
antibodies in normal individuals. Therefore we have made use of
the severe combined immunodeficiency (SCID) mouse as the
non-autoimmune recipient to study the effects of human anti-
DNA antibodies in vivo. This strain of mouse will not reject
foreign cells and has been used for ten years to support the growth
of monoclonal antibodies from different species [7, 8]. We have
injected the hybridomas secreting the human IgG anti-DNA
antibodies into SCID mice to observe and document their binding
capacity in vivo and any ensuing pathological effects.
Methods
Animals
Nine-week-old CB-17-scid/scid (SCID) mice were purchased
from Charles River (Margate, Kent, UK). The SCID mice were
kept in sterile boxes covered by a filter and fed sterile water and
food without any antibiotics. The mice were bled before the
experiment to check for the presence of endogenous murine
antibodies (leakiness). Only those with no detectable murine
immunoglobulin were used for this study.
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Table 1. The isotype and binding properties of monoclonal IgG anti-DNA antibodies derived from two SLE patients
Clone Isotype
Anti-DNA reactivity
ELISA: ssDNA dsDNA Crithidia Fan
B3
D5
32.B9
33.C9
35.21
IgGi, lambda
IgGI, kappa
IgG3, lambda
IgG2, kappa
IgG2, lambda
+
++
+
+
—
++
+
+ +
++
++
+
—
+
+
+
Not tested
Not tested
+
+
Clone Nucleosomes
Heparan
Histones sulphate
Chondroitin
sulphate Laminin
Collagen
type IV
B3 ++ + — — — —
D5 + - -
32.B9 ++ — — — — —
33.C9 -I-+ ++ — — — —
35.21 + — — —
Each antibody was titrated to each antigen starting at 1 g/ml. Scale + + represents OD > 1 at 250 ng/mI, + OD > 0.25 at I g/ml and — for OD
< (blank + 3 SD) at 1 g/ml. No difference was found in the binding to the antigens when the supernatant was treated with DNAase except for the
binding of B3 to histones which was abolished when DNAase was added to the supernatant. Further information on the binding of 32.B9, 33.C9 and
35.21 to other antigens (and their affinities to DNA) can be found in [9]. The affinities of B3 and D5 to DNA can be found in [10].
Table 2. Time to development of ascites (increase of weight by 20%), serum and ascites immunoglobulin concentration and proteinuria as
recorded by Albustix® (Bayer Diagnostics, Berkshire, UK) for the mice that received the hybridomas secreting anti-DNA antibodies detailed in
Table 1.
Number
of mice Hybridoma
.Time to ascites
days
Human Ig Human Ig
ascites serum
.Proteinuria
(dipstick)
mean/rangemean SD, p.g/ml
6 B3 45 10 122 56 124 50 2.4/2-3+
6 D5 37 11 15 6 14 5 0.2/Trace-1+
5 33.21 30 5 556 181 612 174 2.2/2-3+
6 33.C9 41 8 386 121 314 104 2.4/2-3+
5 32.B9 29 7 409 92 422 77 0.8/1-2+
4 CB-F7 28 8 0 0 Trace
4 — — 0 0 Trace
Production of human monoclonal IgG anti-DNA antibodies
Five human monoclonal IgG anti-DNA antibodies were pro-
duced from two patients with active SLE by fusion of the patient's
lymphocytes with the heteromyeloma cell line CBIF7 as described
previously [5, 6]. One of these patients had active nephritis, the
other active arthritis. The designation of these antibodies and
their characteristics are given in Table 1. The B3 and D5
monoclonal antibodies (derived from the patient with active
arthritis) were purified from hybridoma supernatant by affinity
chromatography using a protein G column (Pharmacia, Hertford-
shire, UK) before they were injected intravenously.
Administration of human hybridomas and purified mAb to
SCID mice
The SCID mice were treated with 0.5 ml sterile pristane
[4,6,10,14-tetramethylpentadecane] (Sigma, Poole, Dorset) 10
days prior to intraperitoneal (i.p.) injection of hybridoma cells.
Hybridoma cells producing the monoclonal antibodies were har-
vested from midlog phase cultures and resuspended in 0.5 ml
RPMI so that the total number of cells was 1 X 106 cells. The
original cell lines had been subcloned three times, and were
recloned once immediately prior to injection. The cells were
injected into the peritoneum under sterile conditions using a 21
gauge needle. Five or six mice were used for each antibody
(injected at different times, with different batches of the same cell
line) and four uninjected pristane primed mice and four mice
injected with the non-secreting fusion partner cell line were used
as controls.
Ascites developed in all the mice injected with cells. The mice
were sacrificed either when their body wt increased by 20% due to
the ascites, or if the mice appeared unwell. The urine was checked
for proteinuria using a dipstick (Albustix) and a blood sample was
taken. The peritoneum was opened and the ascites collected. The
kidney, spleen, liver and skin were sampled and part was snap
frozen or fixed in 4% formaldehyde. The ascites and serum were
assayed for the presence of human immunoglobulin and anti-
DNA activity by ELISA as described previously [9, 10].
Intravenous injection of the purified antibody into SCID mice:
1 mg of purified monoclonal antibody (B3 or D5) in 0.2 ml of PBS
was injected into the tail vein of the mouse (4 mice/antibody).
Each mouse was sacrificed six hours after the injection and the
same organs were taken as described above. One milligram of
purified human IgG antibodies (Sigma) was injected as a control.
ELISAs for the analysis of polyreactivily
Anti-histone activity was detected using an ELISA method as
described elsewhere [11]. Briefly, histone type uS (Sigma) was
coated overnight at a concentration of 10 jg/ml at 4°C in PBS.
The plate was then blocked with 2% casein and any DNA
contaminating the histone was removed by treatment with
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Fig. 1. Direct immunofluorescence photograph of a renal tissue section,
stained with a fluoresceinated anti-human IgG antibody, from mice injected
with (a) 33.C9: i magnification X20, ii x40, (b) 35.21: i X20, ii X40, iii
x 100. Only mice that had received 33.C9 had immunoglobulin which was
found exclusively in the glomerulus, forming extracellular deposits in the
capillary wall and mesangium. The antibody 35.21 bound to nuclei with
perinuclear accentuation.
DNAase 1 (Sigma). The supernatants were added to the plate and
antibody bound to the plate was detected using an anti-human
IgG alkaline phosphatase conjugate (Sigma). Heparan sulphate
(50 gglml, Sigma) was bound to an ELISA plate precoated with
protamine sulphate [12]. Nucleosomes (10 g/ml, nucleohistone,
Sigma), laminin [and rabbit anti-laminin antibodies (Sigma) as a
positive control] obtained from mouse Engelbreth-Holm.-Swarm
tumor (10 pg/mI, Sigma), and chondroitin sulphate (10 .tg/ml,
Sigma) were directly bound to the plate diluted in PBS. The plates
were then blocked with 2% casein and after the supernatants were
added, antibody bound was detected as for the histone ELISA.
Each supernatant was tested for reactivity with an antigen un-
coated well in the same plate (or in the case of heparan sulphate,
protamine sulphate) and any binding was subtracted against the
binding to the test antigen. The supernatants were also tested for
antiglomerular basement membrane activity using an ELISA kit
which utilizes the M2 subunit from type IV collagen as substrate
(Bio-diagnostics, Upton, Warwickshire, UK). Antibody contain-
ing supernatants were tested with or without pretreatment with
DNAase 1 as previously described [6].
Immunohistochemical studies
Human immunoglobulin was detected on frozen sections using
goat anti-human IgG fluoresceinated conjugate (1:50; Southern
Biotechnology, Birmingham, AL, USA) which was incubated on
the slides for 30 minutes at room temperature. In addition,
counterstaining with propidium iodide was performed on sections
stained with the goat anti-human IgG fluoresceinated conjugate,
derived from mice that had received hybridomas secreting 35.21,
and viewed using a 630 nm wavelength filter to demonstrate
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nuclear localization. The monoclonal antibodies were also incu-
bated in vitro on sections of untreated SCID mice and binding was
detected using the same conjugate as above. The slides were
washed in phosphate buffered saline and viewed under UV light
(filter set at 530 nm) using an MRC 600 scanning system
connected to image analysis software (BioRad, Hertfordshire,
UK) or using a Nikon microscope attached to a camera. The
formalin fixed material was paraffin embedded for light micros-
copy and epoxy resin embedded for transmission electron micros-
copy. The paraffin sections were stained in routine fashion with
hematoxylin and eosin.
Results
The binding of the antibodies to DNA and other autoantigens
is shown in Table 1. All the antibodies bound to DNA and
nucleosomes with varying affinities, 33.C9 bound strongly to
histones. The antibodies did not bind to any other antigen tested.
Injection of the hybridomas intraperitoneally into the SCID mice
resulted in ascites in all cases. The ascites became clinically
apparent between three to seven weeks after administration. The
human immunoglobulin levels in the ascites and serum were
similar in individual mice. There was a wide range of immuno-
globulin levels between the mice that had received different cell
lines. Table 2 indicates the time to ascites formation, the serum
and peritoneal immunoglobulin level and the degree of protein-
uria.
Mice that had received three of the five antibodies (B3, 35.21,
33.C9) showed evidence of immunoglobulin deposition in tissue.
All the mice that had received the same antibody showed similar
staining patterns (5 or 6 mice per antibody). One antibody, 33.C9,
localized exclusively to the glomeruli forming extracellular depos-
its in the capillary wall and mesangium (Fig. la). 33.C9 was not
found in any of the other tissues examined. Two antibodies (B3
and 35.21) showed binding to nuclear structures with accentuation
of IgG deposition around the nuclear envelope. All the antibodies
were able to bind to the nuclei when they were incubated in vitro
on fixed kidney sections from untreated SCID mice (data not
shown), but only two exhibited this pattern in vivo indicating the
specificity of the phenomenon. Figure lb shows the distribution of
antibody 35.21 in the kidney, the high power view reveals some
heterogeneity in nuclear binding with accentuation of the perinu-
clear areas. These two antibodies also stained cell nuclei at other
sites, such as liver, spleen and skin. Propidium iodide, which binds
to nuclei, was used as a counterstain on sections derived from
mice that had received the hybridoma secreting 35.21 already
stained with an anti-human IgG fluoresceinated conjugate. The
propidium iodide produced a similar pattern to that seen for
immunoglobulin distribution indicating the intranuclear localiza-
tion of the antibody (Fig. 2). Intravenous injection of B3 gave an
identical pattern to that seen with the hybridomas secreting B3.
Administration of the monoclonal antibodies 32.B9 or D5 (as
hybridomas or intravenously) did not lead to immunoglobulin
deposition, either extracellular or intranuclear, in any organ. The
architecture of the kidneys (Fig. 3, 33.C9 antibody) and other
organs from all the mice appeared normal. Electron microscopy
of the kidney sections did not show any electron dense deposits
and there was no significant ultrastructural morphological abnor-
mality (data not shown). However, the mice that had antibodies
deposited in the kidneys all developed significantly more (between
2 to 3+) proteinuria compared to the mice that had received
secreting hybridomas, but did not have immunoglobulin deposited
in tissues (P < 0.001).
Discussion
This study represents the first attempt to transfer human
monoclonal IgG anti-DNA antibodies in vivo and to study their
effects, particularly in terms of antibody deposition. The SCID
mouse provides a unique tool for the analysis of human mono-
clonal antibodies; by growing antibody secreting hybridomas in
SCID mice, high levels of immunoglobulin are achieved over a
relatively long period. There was a similar concentration of
immunoglobulin in the ascites and the blood, suggesting that the
human immunoglobulin was able to penetrate into the blood.
Some of the serum immunoglobulin could have derived from
hybridoma cells that had migrated to the blood compartment. The
immunoglobulin levels varied depending on which antibody was
injected but there was no correlation between the immunoglobu-
un concentration and its presence in tissues.
Only one of the five antibodies (33.C9) bound exclusively to
glomeruli. This demonstrates that human IgG anti-DNA antibod-
ies are capable of binding to glomeruli in vivo. However, it also
demonstrates that not all IgG anti-DNA antibodies are potentially
pathogenic and that the affinity to DNA is not correlated to renal
deposition. Moreover, whereas three of the antibodies bound well
to nucleosomes by ELISA, only one of these deposited in the
glomerulus. Thus the concept that an antibody that can bind to
nucleosomes will also necessarily bind to glomerular structures is
disputed for the human disease. The only difference between
33.C9 and the other clones was its strong binding to histones.
Histones can bind to the glomerulus directly via a charge inter-
action with heparan sulphate and enhance the deposition of
antibodies. Recent work has demonstrated that histones present
in human and murine SLE kidneys were only detected by the use
of antibodies against histones rather than whole nucleosomes
[reviewed in 13]. Thus antibodies that bind histones specifically
may deposit preferentially in the kidney. It is also possible that an
unidentified antigen may be responsible for the binding of 33.C9
to the glomerulus. A mouse monoclonal anti-DNA antibody that
binds to the glomerulus was shown to cross-react with a novel
protein which had sequence homology to the family of SPARC
extracellular matrix proteins [141.
An analysis of the amino acids thought to be important in
binding to DNA and histones is shown in Table 3 (data from
[15—17]). In contrast to the murine data the small number of
human antibodies studied here precludes any conclusions about
distinct pathogenic variable genes. The two antibodies that were
able to penetrate cells and bind to nuclei in vivo are not from the
same germ line gene. The only difference between 33.C9 which
deposited in the glomerulus and the other antibodies is the
smaller number of arginines. In terms of somatic mutation 33.C9
is the only antibody out of the five studied to gain negative charge
and lose arginine residues. In contrast, a recent report found that
there were a higher number of positively and negatively charged
amino acids in the CDRs of the heavy chain of murine pathogenic
anti-DNA antibodies compared to non-pathogenic anti-DNA
antibodies [181. Arginines were found to be absent in the CDRs of
the heavy chains of these murine non-pathogenic antibodies but
present in the pathogens. Arginines are known to be the most
versatile amino acid for binding to DNA, whereas negatively-
charged amino acids are thought to be important in binding to
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Fig. 2. A kidney section derived from a mouse
that had received hybridoma cells secreting 3521.
The section has been labeled with both
propidium iodide (viewed using a 630 nm filter)
which binds to the nucleus, and a
fluoresceinated anti-human IgG antibody
(viewed using a 530 nm filter), demonstrating
that the localization of propidium iodide [1]
and of immunoglobulin [2] was similar and
suggesting that the antibody bound to nuclear
structures (magnification X40).
histones [19]. Future studies will need to concentrate on which
amino acids are accessible for antigen binding and in elucidating
the important antigens that determine the exclusive binding to
glomeruli.
In contrast to the murine monoclonal anti-DNA antibodies that
induced histological evidence of nephritis in normal mice [3],
none of the human antibodies used in this study did so. However,
significant proteinuria was detected in those mice in which
immunoglobulin was deposited. This may be due to the disruption
of anionic sites in the basement membrane which can occur
without any overt histological changes [20]. Fab fragments of
antibodies can induce proteinuria without inducing nephritis,
implying a direct toxic effect of the antibodies. The lack of
immune complexes may be due to the antibody binding directly to
glomerular structures and not forming immune complexes. The
absence of nephritis may be explained by the failure of the human
antibodies to interact with murine complement [21]. This may be
more relevant than the fact that functional B and T cells are not
present in the SCID mouse, since, in a recent report, murine
monoclonal anti-DNA antibodies that induced nephritis in nor-
mal mice also produced an identical picture in SCID mice [22].
Moreover, in the experiments by Raz and coworkers using the
isolated rat kidney, only when complement was added to the
human polyclonal anti-DNA antibodies was there any significant
change in renal function or proteinuria [4].
Two of the antibodies appeared to bind to the nuclei within
cells as has been observed with a subset of murine monoclonal
antibodies [23]. This phenomenon was unlikely to be due to a
staining artifact as only a proportion of the antibodies had this
property. The nuclear localization was not cell specific as it
occurred in a variety of organs. Since all the antibodies were able
to bind to the nucleus in fixed sections of mouse kidney (data not
shown), the capacity of the antibody to show intranuclear local-
ization in vivo must be related to its binding to cell surface and
subsequent internalization. One previous report showed that
murine anti-DNA antibodies did bind to cell surface proteins
present on cells derived from a number of tissues in vitro and that
the binding was not changed by the addition of DNAase [24].
Intranuclear localization has been observed in the kidneys and
other organs of lupus patients [25, 26], but this is the first report
of a human monoclonal antibody directly penetrating cells in vivo.
The proteinuria associated with this phenomenon could be due to
a variety of different causes as discussed for murine monoclonal
antibodies [23], perhaps linked to an interaction with a number of
intracellular processes.
In summary, this study represents the first attempt to investi-
gate the pathogenicity of human anti-DNA antibodies in vivo.
One anti-DNA antibody bound exclusively to glomeruli forming
extracellular deposits, whereas two others were apparently able to
penetrate cells and bind to nuclei in a variety of different organs.
None of the mice developed pathological evidence of glomerulo-
nephritis though proteinuria was a feature in some of the mice.
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Fig. 3. A kidney section (stained with
hematoxylin and eosin) from a mouse that had
received hybridoma cells secreting 33. C9 is shown
viewed under light microscopy (X40). There were
no histopathological changes in any of the mice.
Table 3. The number of amino acids thought to be important in
binding to DNA and histones in the CDR regions of the various
antibodies
32.B9
Positive
4
Negative Asparagine Arginine
1 3 3
B3 5 3 2 5
D5 6 1 5 4
35.21 5 2 3 4
33.C9 5 2 2 1
The amino acids are categorized into negatively and positively charged,
and the number of asparagines (neutral) and arginines (positive) are
shown individually. Note that the light chain sequence of 35.21 has not
been determined. Sequence data are from [15—171.
These results indicate the importance of utilizing monoclonal
antibodies in determining specificity-function relationships, and
that the affinity for dsDNA is not the sole determining factor
governing the biological properties of these antibodies in vivo.
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